Drug Profile
Research programme: antifibrotics - ProQR Therapeutics/Galapagos
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Galapagos NV; ProQR Therapeutics
- Class Antifibrotics; Oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Fibrosis in Belgium
- 28 Feb 2022 No recent reports of development identified for research development in Fibrosis in Netherlands
- 08 Jan 2018 ProQR and Galapagos enters into a collaboration for development of oligonucleotides for Fibrosis